Files

Abstract

Pityriasis Rubra Pilaris (PRP) is a rare and debilitating cutaneous disease characterized by widespread red scaly plaques, follicular papules, and palmoplantar keratoderma. The pathogenesis of PRP is poorly understood, although overexpression of Th17 cytokines have been reported suggesting an inflammatory pathogenesis that may share features with psoriasis. In this study, we used OLINK proximity extension assay technology to quantitate 92 plasma inflammatory proteins of 11 PRP patients treated with ixekizumab (NCT03485976). To our knowledge, this is the first quantitative protein analysis of PRP. These findings support prior studies implicating dysregulation of the Th17 axis in PRP and may help elucidate relevant pathways to target and better treat PRP. Further research is warranted to compare samples to a control population, and to compare these systemic biomarkers to local changes in skin samples.

Details

PDF

Statistics

from
to
Export
Download Full History